Abstract: This article summarizes 8 foreign research articles on the treatment of refractory glaucoma with transscleral cyclophotocoagulation with micropulse laser (MP-TSCPC). There were a total of 453 eyes with refractory glaucoma, including more than 33 eyes with pseudoexfoliative glaucoma, 43 eyes with chronic angle-closure glaucoma, more than 58 eyes with neovascular glaucoma, and more than 264 eyes with primary open-angle glaucoma. Most patients had previously undergone incisional glaucoma surgery or had a history of failed glaucoma surgery. Laser power was from 1.6 to 2 W. The duration of treatment lasts between 100 to 360 seconds, and the total energy used was within range of 62 to 225 J.  Follow-up time was from 2 to 18 months, and the success rate was from 33.3% to 73.7%. The preoperative highest intraocular pressure (IOP) was (39.1±13.84) mmHg, and the postoperative lowest IOP was (11.1±4.4) mmHg. The maximum number of anti-glaucoma eyedrops used preoperatively was 4, while postoperatively it was reduced to a minimum of 1.5 eyedrops. Most postoperative complications were anterior chamber inflammatory reactions, with 2 cases of eyeball atrophy and 15 cases of hypotony being the most severe complications. The studies showed that MP-TSCPC can effectively reduce IOP in refractory glaucoma and is a new treatment modality for refractory glaucoma. (Int Rev Ophthalmol, 2024, 48:  15-19)

Key words: micropulse laser, transscleral cyclophotocoagulation, refractory glaucoma